About: Sunuvion (United Kingdom)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Sunuvion (United Kingdom) Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

company in City of Westminster, United Kingdom

Attributes	Values
rdf:type	Item
description	bedrijf uit Verenigd Koninkrijk (nl) company in City of Westminster, United Kingdom (en)
rdfs:label	Sunuvion (United Kingdom) (en)
skos:prefLabel	Sunuvion (United Kingdom) (en)
name	Sunuvion (United Kingdom) (en)
ROR ID	wds:Q30269364-1FB84BD8-EBA1-4406-9F2C-DDB7AB27C450
ROR ID	03sh4z743
instance of	wds:Q30269364-324ABDED-4EC2-4BF6-A968-4648A63B76A4
instance of	business
country	wds:Q30269364-7E17F7C6-F23A-40FF-B9B5-98BF64415009
country	United Kingdom
inception	wds:Q30269364-748583A3-1118-449E-8608-75C2525DAF16
inception	1984-01-01 00:00:00Z (xsd:dateTime)
headquarters location	wds:Q30269364-17235902-788B-4C2C-BD9E-03C2CE0A4C0D
headquarters location	Westminster
skos:altLabel	Sunovion Pharmaceuticals (en)
OpenAlex ID	wds:Q30269364-13FF23D3-A435-4046-B148-22A51F961C85
official website	wds:Q30269364-FD8DF92A-CDC7-46DE-A61D-9075C326B2CE
OpenAlex ID	I224699690
official website	http://www.sunovion.eu/
GRID ID	wds:Q30269364-8EB81898-8950-4F58-8392-6CB6E6846DD2
parent organization	wds:Q30269364-E5BCE4E5-70C2-491F-97FF-D39C61A634BC
GRID ID	grid.476771.4
parent organization	Sunovion
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q30269364
is has subsidiary of	Sunovion
is sponsor of	Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR). Major Depressive Disorder With Mixed Features - Extension A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis Major Depressive Disorder With Mixed Features Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on) Study of an Evening Dose of Eszopiclone on Next Day Driving Ability & Psychomotor/Memory Function in Healthy Volunteers A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR) Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose Lithium Drug-Drug Interaction Study With Lurasidone HCl This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Diso A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older Effects of One Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD) Study of Eszopiclone Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause/Menopause Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluct A Twelve Week, Open Label Extension Study in Patients With Schizophrenia A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
is has subsidiary of	wds:Q3478870-2BA91377-E49F-4F3D-A33B-72362DC93083
is sponsor of	wds:Q61980958-066D01BD-AC5B-4726-82A5-CE0AAF52275D wds:Q63321746-4E4393EE-742C-4686-8E75-06EB6F8B45E5 wds:Q63811714-9D717596-FB39-43A0-BB7C-A4BADFBF4B16 wds:Q62110164-A670BA55-0833-4785-8F23-C939FE1E8F80 wds:Q61980760-3B2842AD-5EEC-4FF2-8E6C-3EA79666A1F6 wds:Q61933801-22469B79-AC2A-413B-BE08-7BAFF1C9975E wds:Q63321748-6F273F03-8772-4AA6-A734-C541B6636174 wds:Q63336053-6F8B0FA0-F2E7-40B2-BB24-3292B6A79ECD wds:Q61975179-77F526E4-1D55-4D04-AF15-4A0693102E64 wds:Q61980809-0E68E687-B046-470B-A5D7-B1B96942DED4 wds:Q61933770-091A75D4-BF25-484C-9DA6-C065EDF66CC4 wds:Q61933792-9A9CE33A-0318-45C4-B69D-8F5CFCC11AD4 wds:Q61938329-5DDE2E03-FC2C-46A2-9AFA-9F26AA9921F3 wds:Q61965893-FF6DD801-AF8C-48DE-A39F-231B785B6475 wds:Q63322155-BE3E0BE2-8D5E-448F-AE4F-460495BD5B8F wds:Q61938391-B6B7CFD6-F303-40C9-9919-5433CBC7849E wds:Q63315789-F893C422-1C75-4DF6-8E69-F3B13D084416 wds:Q62110165-6491269D-08C9-4A4E-B57B-17DACE990165 wds:Q61967236-40093F28-E28B-4227-A727-E38986FF8F7E wds:Q63316589-C2B759A5-40E6-4671-B220-6145865A5D43 wds:Q61939177-A3473A78-4B40-4479-9DC1-1EC008EF763C wds:Q61933789-972CB263-8C1D-4C16-B658-E2C4D7C1E51A wds:Q61969775-FCC7593E-7584-4B3E-97CB-806D0138130E wds:Q61921596-BE11BF09-6A0D-46F4-B7F2-57DAC1F916AF wds:Q61934211-AF5AEFCA-27E4-4804-9CFC-D59157E34D78 wds:Q61937061-4B2FFA8E-9D61-49EF-A512-51C2DCCBAD84 wds:Q63404902-8B5CA328-5A44-4844-B340-629D6872C173 wds:Q63318493-997CB00B-7A5D-4EFC-96BA-247A40A1ED38 wds:Q63393551-7971C29C-EF7A-4889-AE72-C4EA572101AA wds:Q61914794-76E921FE-EF7E-4398-8EA9-27DAE44AA1CF wds:Q61980785-0F632CA5-82AD-4ACA-A856-CE734CB874B9

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software